Fulgent Genetics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Fulgent Genetics şirketinin toplam hissedar öz sermayesi $1.1B ve toplam borcu $2.9M olup, bu da borç-öz sermaye oranını 0.3% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $1.2B ve $98.9M dir.

Anahtar bilgiler

0.3%

Borç/özkaynak oranı

US$2.91m

Borç

Faiz karşılama oranı	n/a
Nakit	US$213.07m
Eşitlik	US$1.13b
Toplam yükümlülükler	US$98.87m
Toplam varlıklar	US$1.23b

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 7F0 'nin kısa vadeli varlıkları ( $326.5M ) kısa vadeli yükümlülüklerini ( $74.0M ) aşıyor.

Uzun Vadeli Yükümlülükler: 7F0 şirketinin kısa vadeli varlıkları ( $326.5M ) uzun vadeli yükümlülüklerini ( $24.9M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 7F0 şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: 7F0 şirketinin borç/öz sermaye oranı son 5 yılda 0% seviyesinden 0.3% seviyesine yükseldi.

Borç Kapsamı: 7F0 'nin borcu işletme nakit akışı ( 377.8% ) tarafından iyi bir şekilde karşılanmaktadır.

Faiz Kapsamı: 7F0 şirketinin borçlarına ilişkin faiz ödemelerinin EBIT tarafından iyi bir şekilde karşılanıp karşılanmadığını belirlemek için yeterli veri yok.

Fulgent Genetics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Third quarter 2024 earnings released: US$0.48 loss per share (vs US$0.44 loss in 3Q 2023)

Fulgent Genetics, Inc. Reiterates Earnings Guidance for the Year 2024

New minor risk - Shareholder dilution

Fulgent Genetics, Inc. to Report Q3, 2024 Results on Nov 08, 2024

Second quarter 2024 earnings released: US$0.29 loss per share (vs US$0.38 loss in 2Q 2023)

Fulgent Genetics, Inc. Revises Earnings Guidance for the Year 2024

Fulgent Genetics, Inc. to Report Q2, 2024 Results on Aug 02, 2024

First quarter 2024 earnings released: US$0.45 loss per share (vs US$0.52 loss in 1Q 2023)

Fulgent Genetics, Inc. to Report Q1, 2024 Results on May 03, 2024

Fulgent Genetics, Inc., Annual General Meeting, May 16, 2024

Fulgent Genetics, Inc. Provides Earnings Guidance for the Year 2024

Fulgent Genetics, Inc. Provides Earnings Guidance for the Year 2024

Full year 2023 earnings released: US$5.64 loss per share (vs US$4.77 profit in FY 2022)

Fulgent Genetics, Inc. to Report Q4, 2023 Results on Feb 28, 2024

COO & President recently sold €543k worth of stock

New minor risk - Share price stability

Fulgent Genetics, Inc. Announces Two Poster Presentations At SITC 2023 Annual Meeting

Third quarter 2023 earnings released: US$0.44 loss per share (vs US$0.057 profit in 3Q 2022)

Fulgent Genetics, Inc. to Report Q3, 2023 Results on Nov 03, 2023

Chief Financial Officer recently sold €320k worth of stock

Second quarter 2023 earnings released: US$0.38 loss per share (vs US$0.38 profit in 2Q 2022)

Fulgent Genetics, Inc. Provides Earnings Guidance for the Third Quarter of 2023 and Full Year 2023

Fulgent Genetics, Inc. Announces Data from a Phase 1/1b Clinical Study of FID-007 in Treating Various Solid Tancers

First quarter 2023 earnings released: US$0.52 loss per share (vs US$5.09 profit in 1Q 2022)

Fulgent Genetics, Inc. Provides Earnings Guidance for the Second Quarter of 2023 and Full Year 2023

Full year 2022 earnings released: EPS: US$4.77 (vs US$17.25 in FY 2021)

Fulgent Genetics, Inc. to Report Q4, 2022 Results on Feb 28, 2023

Fulgent Genetics, Inc. Appoints Reggie Groves to Its Board of Directors

Fulgent Genetics, Inc., Annual General Meeting, May 01, 2023

Chief Financial Officer recently sold €62k worth of stock

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: US$0.057 (vs US$4.13 in 3Q 2021)

Fulgent Genetics, Inc. (NasdaqGM:FLGT) acquire Fulgent Pharma Holdings, Inc for approximately $100 million.

Fulgent Genetics, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2022

Fulgent Genetics, Inc. Announces Resignation of Leonard Post from the Board and as the Chair of the Nominating and Corporate Governance Committee

The Klein Law Firm Files Class Action Complaint on Behalf of Shareholders of Fulgent Genetics, Inc

Fulgent Genetics, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Less than half of directors are independent

Fulgent Genetics, Inc. Announces Resignation of John Bolger from the Board

Pomerantz Law Firm Announces the Filing of A Class Action Against Fulgent Genetics, Inc

Chief Financial Officer recently sold €94k worth of stock

Investor sentiment deteriorated over the past week

Fulgent Genetics, Inc. Provides Earnings Guidance for the Third Quarter and Full Year of 2022

Second quarter 2022 earnings released: EPS: US$0.38 (vs US$2.74 in 2Q 2021)

Fulgent Genetics, Inc. Announces Launch of PCR Based Test to Detect Monkeypox

Fulgent Genetics, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Helio Genomics and Fulgent Genetics Announces That American Medical Association Approves A New Category I Cpt® Code for the Helioliver™ Test

Chief Financial Officer recently sold €61k worth of stock

First quarter 2022 earnings released: EPS: US$5.09 (vs US$6.96 in 1Q 2021)

Fulgent Genetics, Inc. Provides Earning Guidance for Second Quarter of 2022

Fulgent Genetics, Inc. Announces Executive Appointments

Fulgent Genetics, Inc. Revises Revenue Guidance for the First Quarter Ended March 31, 2022 and Full Year Ended December 31, 2022

Fulgent Genetics, Inc., Annual General Meeting, May 18, 2022

Investor sentiment deteriorated over the past week

Fulgent Genetics, Inc. Provides Earning Guidance for the First Quarter and Full Year of 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Fulgent Genetics, Inc. to Report Q4, 2021 Results on Feb 23, 2022

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Chief Operating Officer recently sold €54k worth of stock

Chief Operating Officer recently sold €102k worth of stock

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS US$4.13 (vs US$2.11 in 3Q 2020)

Chief Operating Officer recently sold €99k worth of stock

Second quarter 2021 earnings released: EPS US$2.74 (vs US$0.15 in 2Q 2020)

Fulgent Genetics, Inc. (NasdaqGM:FLGT) acquired CSI Laboratories, Inc.

Investor sentiment improved over the past week

Fulgent Genetics, Inc.(NasdaqGM:FLGT) dropped from Russell 3000E Index

Chief Financial Officer recently sold €75k worth of stock

Investor sentiment improved over the past week

Chief Operating Officer recently sold €115k worth of stock

First quarter 2021 earnings released: EPS US$6.96 (vs US$0.091 loss in 1Q 2020)

Fulgent Genetics, Inc. Provides Revenue Guidance for the Full Year of Fiscal 2021